Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 18 Apr 2017 Planned primary completion date changed from 28 Feb 2019 to 1 Feb 2019.
- 15 Feb 2017 Planned number of patients changed from 143 to 148.